At the post-transcriptional level, gene expression is largely regulated through a network of molecular machines that regulate pre-mRNA maturation integrity, transport, translation and degradation. These processes are based on the formation of nucleoprotein complexes and require the recognition of sequence motifs on the RNA. By masking these targets with complementary RNA sequences forming Watson-Crick base pairing, it is possible to efficiently and specifically impact on the cell phenotype, or to compensate the deleterious effect of mutations. Here we review how the adeno-associated virus technology is being exploited for expressing non-coding RNAs in tissues such as the brain, muscle or liver, in functional genomic studies as well as for the development of novel therapeutic strategies.
Vector technologies for expressing exogenous ncRNAs
Naturally occurring RNA-mediated regulations were first documented in prokaryotes in the 1970s, 1 and early gene transfer experiments in mammalian cells have established the potential of antisense sequence delivery for studying gene function and developing therapeutic approaches. 2 A large number of studies used polymerase II expression cassettes to produce antisense transcripts of a few hundred nucleotides in transfected cells. Under these conditions, the target RNA is edited and retained in the nucleus, leading to expression knockdown. 3 This technology has been largely replaced by transfecting short synthetic antisense RNAs capable of inducing degradation of RNA with complementary sequences through the specialized RNA degradation cascade of RNA interference conserved among eukaryotes. 4 Ribozymes, catalytic RNAs that act either in cis or in trans, represent a different set of versatile tools for recognizing and cleaving cellular mRNAs. 5 Spliceosome assembly can be precisely altered using antisense sequences that mask key splicing signals and compete with the binding of spliceosomal proteins or associated small nuclear (sn) RNAs. 6 As a result, it is possible to exclude or include specific exons from the mature mRNA. Finally, antisense sequences have also been used to tether exogenous exons to an mRNA in a process called trans-splicing, which may be used to repair mRNAs or to create fusion proteins. 7, 8 When short RNAs are introduced into cells as synthetic oligonucleotides, they are active for a limited period of time and sustained effects can only be seen when a stable gene transfer system is used. Most viral vectors have been adapted for the delivery of non-coding RNAs (ncRNAs) in tissue culture and in vivo. 9 Among them, adeno-associated virus (AAV) offers the advantage of stable long-term expression after systemic or localized in vivo administration. The vectors introduce multiple extrachromosomal copies of the transgene in cells and display a variety of tissue tropisms, depending on the type of capsid used in the packaging system. 10, 11 The importance of retroviral or lentiviral vectors in RNA interference studies has been amply demonstrated, 12 but, in some circumstances, the AAV vector may be advantageous. The retroviral vector RNA genome that carries short hairpin RNAs (shRNAs) can itself be targeted for destruction by the interference machinery induced in the producer cells during the vector production. As a consequence, the vector titre was significantly reduced. 13 This effect may be more or less severe depending on the shRNA and could introduce a bias in libraries used in genomic screens.
The inclusion of ncRNA expression cassettes into AAV does not require any special adaptation, and their design has been reviewed elsewhere.
9,14 AAV vectors have been constructed with classical RNA polymerase III promoterbased expression cassettes for shRNA (human or murine U6, H1); alternatively, AAV vectors incorporating modified snRNA (U7 or U1) for targeting short antisense sequences to the spliceosome were described. 15, 16 Ribozymes and antisense sequences are usually expressed from standard polymerase II-driven cassettes featuring strong promoters. Ribozyme cassettes often contain a second hairpin ribozyme positioned downstream for the precise release of the hammerhead ribozyme from the primary transcript of the vector. These cassettes are small, and even in the size-constrained context of AAV, there is usually enough room for a second transcription unit. This additional cassette may express reporter proteins, for example, green fluorescent protein or luciferase, which offer convenience for tracking vector distribution in vivo. It can also encode a knockdown resistant normal allele, for suppression/replacement strategies 17 (see below). The use of AAV vectors has permitted Grimm et al. 18 to observe and analyze the in vivo toxicity of RNA interference. AAV2/8 vectors encoding a variety of shRNAs, frequently resulted in severe liver toxicity and death when injected intravenously into mice. The study indicated that the stably expressed shRNAs compete with the microRNA processing machinery, resulting in hepatocyte death and ultimately organ failure. Exportin 5 was shown to be the limiting cellular factor in this process. The solution to this problem is to design vectors with expression levels below the toxic threshold but that remain beneficial. This might be difficult to predict in different tissues and challenging to control efficiently, mainly because the expression levels primarily depend on the initial multiplicity of infection. It will be more realistic to use inducible promoters to drive shRNA transcription. Inducible gene expression cassettes have been shown to work well in the context of AAV vectors, 19 and they can be readily adapted for shRNA expression. 20 
Applications in the central nervous system
Adeno-associated virus vectors are powerful tools for direct gene transfer in the central nervous system. Major insights into the molecular mechanisms of learning and memory have been obtained through experimental approaches using transgenic technologies in mouse, fly and worm. Yet, relevant quantitative behavioural assays are obtained only from larger mammals including rats 21 where homologous recombination-based transgenic technology is not readily available nor practical. AAVmediated knockdown of candidate genes has been demonstrated in the rat, and should be feasible in nonhuman primates. By delivering the vectors by stereotaxic injection and using viral capsids from relevant serotypes, it is possible to limit gene transfer to a region of interest, for example, to the hippocampus or the cerebellum. In addition, the retrograde transport of AAV particles in neurons may be exploited to reach extended neuroanatomical structures from a single injection site. 22, 23 Hippocampal neurogenesis can be induced by housing adult rats in an 'enriched' environment. Using AAV vectors, Cao et al. 24 have obtained evidence that this neural remodelling process is mediated by vascular endothelial growth factor. An AAV vector carrying an shRNA against vascular endothelial growth factor was packaged with a mixture of AAV1 and AAV2 capsid proteins and injected into the dorsal hippocampus of adult rats. The injected animals were significantly less responsive to the enriched environment than the controls, and displayed reduced neurogenesis, as measured by 5-bromo-2-deoxyuridine incorporation in the dentate gyrus. 24 In another study, the local reduction of calcium/calmodulin-dependent protein kinase II in the hippocampus of rats was achieved following injection of an AAV2/1 vector with a U6-shRNA cassette. Behavioural testing indicated a significant impairment in place learning and changes in exploratory behaviour. 25 Genetic dominant diseases affecting brain function may be amenable to AAV-shRNA-based therapy. For most of these diseases, the destruction of the mRNA must be allele-specific because the wild-type copy is needed for normal cell function. Proof-of-concepts were reported in mouse models of spinocerebrellar ataxia type 1 and Huntington disease (HD). Xia et al. 26 have evaluated the ability of shRNAs to inhibit neuronal degeneration in a mouse model of spinocerebrellar ataxia type 1, in which a mutated human polyglutamine expansion mutant ataxin-1 gene is expressed over a normal background. AAV-2/1 vectors containing optimized shRNAs against human ataxin-1 expressed from the H1 promoter and a green fluorescent protein expression cassette were prepared and injected into the cerebellum of the animals. This resulted in significant improvements in motor coordination tested between 11 and 21 weeks after injection, as measured by the Rotarod performance test. Compared to the contralateral control vector treatment, the histopathological features of Purkinje cells were considerably improved. These effects were obtained with less than 10% of Purkinje cells transduced as assayed by green fluorescent protein expression.
In humans, HD is a much more prevalent polyglutamine expansion disease than spinocerebrellar ataxia type 1 and results from the neurotoxic effects caused by aggregates of Huntingtin protein (Htt). Therefore, to test the shRNA knockdown approach for a more clinically relevant disease, Harper et al. 27 designed an shRNA that specifically targets the transcript from a human Htt mutant allele for depletion, in a transgenic mouse model of HD. AAV2/1 vectors with U6 promoter-expressed shRNA against Huntingtin transcripts were produced and injected into the striatum and cerebellum of HD mice. The shRNA was expressed for more than 5 months, and behavioural improvement was measured in assays of stride length and rotarod performances. In addition, histology revealed that characteristic immunoreactive Htt aggregates did not form in the striatum and cerebellum any longer. Other studies have confirmed the effect of intrastriatal shRNA delivery in other, more aggressive murine models of HD using AAV2/5 vectors. 28, 29 It has been possible to model features of Parkinson's disease with AAV vectors encoding shRNAs against tyrosine hydroxylase, a key enzyme in the production of dopamine by the neurons of the substantia nigra that undergo degeneration during the course of the disease. Injection in the ventral tegmental area of mice resulted in dopamine deficiency and behavioural abnormalities. 30 Alpha-synuclein is involved in the formation of toxic aggregates in neurodegenerative diseases including Parkinson's disease. An AAV vector carrying a ribozyme against a-synuclein was designed and tested for protection against apoptotic death of dopamine neurons in a pharmacologically induced, 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine model of Parkinson's disease in rats. The treatment did increase survival of tyrosine hydroxylase-positive neurons, establishing a proof of principle for a-synuclein downregulation as an RNA-based therapeutic approach in Parkinson's disease. 31 AAV
Haberman et al. 32 have suppressed the activity of the N-methyl-D-aspartic acid receptor involved in focal seizure disorders by injecting recombinant adeno-associated virus with an antisense sequence expression cassette into the brain of rats. Interestingly, opposite effects on seizure sensitivity in the injected animals were observed, depending on the site of injection where distinct neuron types expressed the antisense sequence. This illustrates the difficulty of precisely targeting relevant cell types in the brain. In this respect, using the full arsenal of vector pseudotypes and serotypes and cell type-restricted transcriptional cassettes should allow progress to be made.
Eye and ear
10 RNA suppression by interference, antisense and using a ribozyme have been tested as approaches for the treatment of dominant forms of retinitis pigmentosa, a degenerative disease with a very high level of genetic heterogeneity and over 40 genes involved. The rhodopsin mRNA, in which over a 100 disease-causing mutations have been described, can be knocked down efficiently in the photoreceptor cells with ribozymes or shRNAs expressed from subretinally injected AAV2/5 vectors. A mouse dominant allele (P23H) expressed in a rat transgenic line causes a progressive loss of photoreceptors. Diverse strategies have been investigated to knock down the pathogenic mRNA with allelespecific, 33, 34 or species-specific 35 ribozymes. AAV2/2 or AAV2/5 vectors were shown to express the ribozymes from an opsin promoter for up to 8 months resulting in P23H mRNA knockdown levels around 50%, with significant attenuation of retinal degeneration. In the same model, a P23H allele-specific shRNA was expressed from a polymerase II U1 promoter and achieved over 60% knockdown. 36 Yet in this case, the residual levels of mutant mRNA escaping degradation were enough to maintain the pathology in contrast with the ribozyme studies. O'Reilly et al. 37 have used a more sophisticated transgenic mouse expressing a human P23H mutant allele in an RHO-null background. In this context, the mutant allele was efficiently eliminated (over 90%) with an allele-independent shRNA and replaced by a codon-modified and silencing-resistant human RHO cDNA. This establishes a proof of concept for an allele-independent suppression and replacement approach for human dominant retinopathies associated with mutations in the RHO gene.
Usher syndrome type 3 is caused by mutations in the USH-3 gene that encodes clarin-1, a tetraspanin thought to play a structural role in maintenance of synapses between primary sensory cells and second-order interneurons. The disease involves sensorineural hearing loss, retinitis pigmentosa and vestibular dysfunction. The role of clarin-1 was investigated in the mouse using an AAV2 vector expressing a hammerhead ribozyme under the hybrid CMV/chicken b-actin (CBA) promoter and inner ear injections. The vector was able to transduce most cell types and anatomical structures of the inner ear, and the presence of the ribozyme was associated with an increased level of apoptosis at 1 month in neurosensory cells, as observed in Usher syndrome. 38 RNA knockdowns have been achieved with AAV vectors in sensorineural cells, with the purpose to understand the mechanisms of cellular degeneration that take place in a number of genetic and acquired diseases. An AAV ribozyme vector was shown to be effective in reducing the levels of cyclic GMP-phosphodiesterase in rod photoreceptors of mice. 39 This enzyme is critical for the visual phototransduction cascade in the vertebrate retina and mutated in human patients with retinitis pigmentosa. In this study, the g subunit was targeted with a ribozyme expressed from the opsin promoter, resulting in significant alterations of the electroretinogram and of the retina morphology. Qi et al. 40 have tested the activity of an AAV2 vector encoding a ribozyme directed against a mitochondrial antioxidant (manganese superoxide dismutase, SOD2) after intravitreal injection into the eyes of mice with experimental allergic encephalitis. An increase in reactive oxygen species and in optic nerve myelin injury was caused by ribozyme expression in this model, whereas overexpression of SOD2 from another vector had an antagonistic effect. When a similar vector targeting SOD2 was subretinally injected in normal mice, increased markers of oxidative damage were found in the retinal pigmented epithelium-choroid, and a severe degenerative pathology, similar to age-related macular degeneration, developed. 41 The efficiency of the technology for rapid and longlasting gene knockdowns in the retinal epithelium was illustrated by Paskowitz et al. 42 who used a U6-shRNA cassette on a 'stabilized double strand' AAV2/5 vector. 18, 42 The study was designed to reduce the levels of basic fibroblast growth factor and document the consequences in the neuroprotective response of the retina to light stress. It is a good example of how a complex physiological unit can be accessed and studied by somatic gene transfer in adult animals using AAV vectors.
Heart and muscle
Surprisingly, very few reports have been published describing AAV-mediated knockdowns in skeletal and cardiac muscles considering the transduction efficiency in these tissues and the potential for both physiological studies and therapeutic applications. Andino et al. 43 have used AAV2/1 vectors to express shRNA against phospholamban by direct injection in the mouse heart. Reducing the level of this peptide inhibitor of the sarcoplasmic reticulum ATPase led to cardiomyocyte shortening and relaxation, and to a decrease in the time constant of calcium decay, indicating a significant impact on cardiac function. Current studies in the skeletal muscle focus on modulating the levels of myostatin (GDF8), which negatively regulates muscle growth. Significant increases in muscle mass can be observed after intramuscular delivery of DNA plasmids encoding anti-myostatin shRNA. 44 AAV-mediated delivery allows for systemic or regional (isolated limb) delivery and results in sustained muscle hypertrophy (L Garcia, personal communication).
Antisense-mediated exon skipping is a potential therapy for Duchenne muscular dystrophy, a disease caused by mutations in the very large, 79 exon-containing, dystrophin gene. Dystrophin has a central rod domain composed of repeated spectrin-like units, and proteins lacking one or several of these repeats, called mini-or micro-dystrophins, often retain function. It has therefore been proposed that exon skipping could be used to exclude mutated exons from the final dystrophin mRNA or to restore the translational phase in the frequent cases of out-of-frame deletions. Goyenvalle et al. 45 have constructed an AAV1/2 vector containing a modified U7 snRNA gene targeted to the spliceosome 15 and carrying antisense that recognized the murine dystrophin pre-mRNA around the splice donor of exon 23 and branching point in intron 22. The dystrophindeficient mdx mouse contains a mutation in exon 23 creating a premature stop codon. The expression of the AAV exon-skipping construct in the skeletal muscle of mdx mice resulted in the exclusion of the mutated exon and in the sustained synthesis of near wild-type levels of dystrophin. Muscle resistance to mechanical stress, which is typically lost in Duchenne muscular dystrophy, was restored in whole limbs perfused with the AAV vector. 45 Transcriptome analysis in transduced mdx muscles indicated normalization of the muscle signature mRNAs: decreased mRNA species were associated with inflammation but not with unwanted perturbations that could have been due to a general toxic effect of the antisense sequences on splicing or mRNA stability. 46 Denti et al. 47 have designed a different antisense shuttle based on the U1 snRNA to carry antisense sequences for exon 23 skipping. This study also included systemic delivery of the AAV2/1 vector, widespread expression of the therapeutic snRNA in skeletal muscle, heart and diaphragm, and rescue of dystrophin expression. When expressed from the U1 promoter and compared to exon 23 skipping, U7 and U1 snRNAs performed equally well as antisense carriers. 16 Synthetic oligonucleotides have now proved efficient for skipping exon 51 on the dystrophin pre-mRNA when administered into patients 48 and AAV vectors containing similar sequences are currently being developed for future clinical trials.
Studies of complex syndromes with ncRNAs
Non-coding RNAs delivered in vivo with AAV vectors provide a tool to probe the complex circuits underlying essential physiological processes like food intake or blood pressure regulation. The influence of neuropeptide Y (NPY) on food intake and weight gain was studied in rats with an AAV vector expressing an antisense sequence against the peptide. Decreased levels of NPY were documented in hypothalamic explants of adult animals injected in the arcuate nucleus and were associated with low food intake and smaller weight gain over the 50 days of the study. 49 Paradoxically, these effects are not seen in the mouse NPY knockout where compensatory rewiring of the appetite-controlling system may occur. The study illustrates that a transgenic approach provides only a partial picture of given pathway and that analyzing the system using nonsomatic gene transfer provides a complementary and sometimes contrary set of results, depending on developmental effects, tissue specificity, and so on. The receptor for leptin, a critical hormone of food intake and metabolism, was knocked down by injecting an AAV vector in the ventral tegmental area of rats. Dopamine neurons were transduced as documented by green fluorescent protein expression, and the RNA interference-mediated long-term reduction of the amount of leptin receptors led to increased food intake and locomotor activity, providing functional evidence for direct action of a peripheral metabolic signal on ventral tegmental area dopamine neurons. 50 Adeno-associated virus vectors have been useful in studies of the renin-angiotensin system in animal models of hypertension. Spontaneous hypertensive rats received an intracardiac injection of an AAV2 vector expressing an antisense sequence against angiotensinogen (CMV promoter). This led to a delayed onset of hypertension and an attenuated disease. 51 Cold-induced hypertension was attenuated when a U6-driven shRNA against the mineralocorticoid receptor was systemically delivered by an AAV2 vector in rats 52 and mice. 53 A 50% reduction in expression of the receptor was documented in the kidney where hypertrophy was attenuated, but not in the heart or aorta. The precise cellular targets of the active vector remain to be characterized. 52 In a rat model of salt hypertension induced by salt loading, an AAV expressing an antisense sequence against the central a2B-adrenergic receptor was administered by intracerebroventricular injection. It resulted in a twofold decrease in protein levels in the cerebellum and hippocampus, and a long-lasting fall in blood pressure. 54 
Conclusion
The intent of this limited review was to provide examples and illustrate ncRNA applications using AAV vectors. The published work so far indicates that the combination of the two will certainly grow in interest and that we are only beginning to explore the possibilities. Although several groups are actively involved, the targeting of mRNAs with a trans-splicing substrate has only been reported in one situation (CFTR) in the context of AAV. 55 Little has been done so far in using AAV for delivering shRNAs, individually or as libraries, into the liver, skeletal muscle and heart, where gene knockdowns will bring new information relative to organ function, homoeostasis, regeneration and pathologies. Even in the brain, where tantalizing data have been reported, the approach is in its infancy. The efficiency and specificity of AAV vectors for all these organs have dramatically improved, but more sophisticated-inducible, tissuespecific-expression cassettes need to be incorporated into these vectors to better control the delivered dose of ncRNA and to avoid toxicities. In each organ, the exact cellular tropism of the vector needs to be defined. Dose and target cell control will be a central concern if the approach is to be used for the study of complex physiological systems. In fact, the full power of the technology will only be unleashed if a true quantitative vector biology is developed first.
